The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Booking ...

AbbVie’s two immunology mainstays, Rinvoq and Skyrizi, which often took the top two spending spots throughout 2024, fell to third and fourth, respectively, this time around. With $42.5 million ...

To curate this list, he dives into Max’s catalogue every month to surface exciting, white-knuckle action titles — using his taste and a lifetime of cinema study as his guide, instead of ...

But sometimes you don’t want that! Sometimes you just want to escape the increasingly insane world out there into an action movie. Netflix has made a few of their own, but the bulk of the best ...

Rinvoq total sales were more than $1.8 billion ... we reinstated our original Alle consumer loyalty program earlier this month. This action has been met with a rapid and favorable response ...

The decline was offset by sales of its newer arthritis drugs Skyrizi, which soared by 57% to $3.78 billion, and Rinvoq, which logged a 46% gain to $1.83 billion. Chief Executive Robert Michael ...

a Represents net earnings attributable to AbbVie Inc. Intangible asset impairment primarily reflects partial impairment charges related to the U.S. Imbruvica and CoolSculpting intangible assets ...

As its shares pop in Friday's session, pharmaceutical giant AbbVie Inc. (ABBV) posted a fourth quarter revenue beat and raised its long-term sales guidance for new drugs Skyrizi and Rinvoq by $4 ...

AbbVie raises 2027 revenue forecast for Skyrizi and Rinvoq to $31 billion ... revenue growth rate for aesthetics through 2029. Price Action: ABBV shares are trading higher by 7.87% to $189. ...

In particular, recently launched drugs Skyrizi and Rinvoq have shown improved efficacy ... data emerges that might require relatively quick action. Also, a strong balance sheet helps biopharma ...